{"entity":{"type":"insider","cik":"0001543904","url":"/insider/0001543904","json_url":"/insider/0001543904.json","name":"QVT Fund V LP","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":37,"n_filings":12,"first":"2013-07-05","last":"2019-06-06","span_basis":"filed_date"},"name_variants":[{"name":"QVT Fund V LP","source":"filing","n_filings":12,"first_seen":"2013-07-05","last_seen":"2019-06-06"}],"transactions":[{"id":8580720,"accession":"0000899243-19-015895","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-19-015895","line_url":"/filing/0000899243-19-015895#line-1","is_derivative":false,"issuer_cik":"0001290166","issuer_name":"Myovant Sciences Ltd.","issuer_ticker":"MYOV","issuer_name_source":null,"issuer_url":"/issuer/0001290166","owner_cik":null,"owner_name":"QVT Fund V LP; QVT Associates GP LLC","owner_display_name":"QVT Fund V LP","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Shares, $0.000017727 par value per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":2424242.0,"shares_display":"2,424,242","price_per_share":8.25,"price_display":"8.25","price_state":"stated","total_value":19999996.5,"total_display":"19,999,996.50","total_whole":"19,999,997","shares_owned_after":40765599.0,"shares_owned_after_display":"40,765,599","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-06-04","filed_date":"2019-06-06","scope":"insider"},{"id":6812587,"accession":"0000899243-18-026091","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-18-026091","line_url":"/filing/0000899243-18-026091#line-1","is_derivative":false,"issuer_cik":"0001290166","issuer_name":"Urovant Sciences Ltd.","issuer_ticker":"UROV","issuer_name_source":null,"issuer_url":"/issuer/0001290166","owner_cik":null,"owner_name":"QVT Associates GP LLC; QVT Fund V LP","owner_display_name":"QVT Associates GP LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Shares, par value $0.000037453 per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":2678571.0,"shares_display":"2,678,571","price_per_share":14.0,"price_display":"14.00","price_state":"stated","total_value":37499994.0,"total_display":"37,499,994.00","total_whole":"37,499,994","shares_owned_after":22703669.0,"shares_owned_after_display":"22,703,669","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-10-01","filed_date":"2018-10-03","scope":"insider"},{"id":6619011,"accession":"0000899243-18-015353","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-18-015353","line_url":"/filing/0000899243-18-015353#line-1","is_derivative":false,"issuer_cik":"0001290166","issuer_name":"Axovant Sciences Ltd.","issuer_ticker":"AXON","issuer_name_source":null,"issuer_url":"/issuer/0001290166","owner_cik":null,"owner_name":"QVT Associates GP LLC; QVT Fund V LP","owner_display_name":"QVT Associates GP LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Shares, $0.00001 par value per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":14285714.0,"shares_display":"14,285,714","price_per_share":1.75,"price_display":"1.75","price_state":"stated","total_value":24999999.5,"total_display":"24,999,999.50","total_whole":"25,000,000","shares_owned_after":89285714.0,"shares_owned_after_display":"89,285,714","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-06-05","filed_date":"2018-06-07","scope":"insider"},{"id":6216703,"accession":"0000899243-18-009452","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-18-009452","line_url":"/filing/0000899243-18-009452#line-1","is_derivative":false,"issuer_cik":"0001290166","issuer_name":"Myovant Sciences Ltd.","issuer_ticker":"MYOV","issuer_name_source":null,"issuer_url":"/issuer/0001290166","owner_cik":null,"owner_name":"QVT Associates GP LLC; QVT Fund V LP","owner_display_name":"QVT Associates GP LLC","owner_url":null,"role":"Director, Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Shares, $0.000017727 par value per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1110015.0,"shares_display":"1,110,015","price_per_share":20.27,"price_display":"20.27","price_state":"stated","total_value":22500004.05,"total_display":"22,500,004.05","total_whole":"22,500,004","shares_owned_after":38341357.0,"shares_owned_after_display":"38,341,357","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-04-02","filed_date":"2018-04-04","scope":"insider"},{"id":8456534,"accession":"0001209191-15-003951","txn_seq":14,"anchor":"line-14","filing_url":"/filing/0001209191-15-003951","line_url":"/filing/0001209191-15-003951","is_derivative":false,"issuer_cik":"0001098972","issuer_name":"AGENUS INC","issuer_ticker":"AGEN","issuer_name_source":null,"issuer_url":"/issuer/0001098972","owner_cik":null,"owner_name":"QVT Associates GP LLC; QVT Fund V LP","owner_display_name":"QVT Associates GP LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock, $0.01 par value","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2343630.0,"shares_display":"2,343,630","price_per_share":5.312835959601132,"price_display":"5.31","price_state":"stated","total_value":12451321.74,"total_display":"12,451,321.74","total_whole":"12,451,322","shares_owned_after":7423440.0,"shares_owned_after_display":"7,423,440","ownership_form":"I","is_10b5_1":null,"transaction_date":"2015-01-09","filed_date":"2015-01-13","scope":"insider","n_lines":14},{"id":6188013,"accession":"0001209191-14-012941","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-14-012941","line_url":"/filing/0001209191-14-012941#line-2","is_derivative":false,"issuer_cik":"0001367920","issuer_name":"CONCERT PHARMACEUTICALS, INC.","issuer_ticker":"CNCE","issuer_name_source":null,"issuer_url":"/issuer/0001367920","owner_cik":null,"owner_name":"QVT Fund V LP; QVT Associates GP LLC","owner_display_name":"QVT Fund V LP","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock, $0.001 par value","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":300000.0,"shares_display":"300,000","price_per_share":14.0,"price_display":"14.00","price_state":"stated","total_value":4200000.0,"total_display":"4,200,000.00","total_whole":"4,200,000","shares_owned_after":559999.0,"shares_owned_after_display":"559,999","ownership_form":"I","is_10b5_1":null,"transaction_date":"2014-02-19","filed_date":"2014-02-21","scope":"insider"},{"id":4883558,"accession":"0001181431-13-052021","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001181431-13-052021","line_url":"/filing/0001181431-13-052021","is_derivative":false,"issuer_cik":"0001070336","issuer_name":"ACHILLION PHARMACEUTICALS INC","issuer_ticker":"ACHN","issuer_name_source":null,"issuer_url":"/issuer/0001070336","owner_cik":null,"owner_name":"QVT Fund V LP; QVT Associates GP LLC","owner_display_name":"QVT Fund V LP","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock, $0.001 par value","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2754900.0,"shares_display":"2,754,900","price_per_share":3.4726512759083814,"price_display":"3.47","price_state":"stated","total_value":9566807.0,"total_display":"9,566,807.00","total_whole":"9,566,807","shares_owned_after":11962953.0,"shares_owned_after_display":"11,962,953","ownership_form":"I","is_10b5_1":null,"transaction_date":"2013-09-30","filed_date":"2013-10-02","scope":"insider","n_lines":3},{"id":5258239,"accession":"0001181431-13-044176","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001181431-13-044176","line_url":"/filing/0001181431-13-044176#line-2","is_derivative":false,"issuer_cik":"0001070336","issuer_name":"ACHILLION PHARMACEUTICALS INC","issuer_ticker":"ACHN","issuer_name_source":null,"issuer_url":"/issuer/0001070336","owner_cik":null,"owner_name":"QVT Associates GP LLC; QVT Fund V LP","owner_display_name":"QVT Associates GP LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock, $0.001 par value","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":65982.0,"shares_display":"65,982","price_per_share":6.37,"price_display":"6.37","price_state":"stated","total_value":420305.34,"total_display":"420,305.34","total_whole":"420,305","shares_owned_after":14467853.0,"shares_owned_after_display":"14,467,853","ownership_form":"I","is_10b5_1":null,"transaction_date":"2013-08-09","filed_date":"2013-08-12","scope":"insider"},{"id":5258233,"accession":"0001181431-13-044176","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001181431-13-044176","line_url":"/filing/0001181431-13-044176#line-1","is_derivative":false,"issuer_cik":"0001070336","issuer_name":"ACHILLION PHARMACEUTICALS INC","issuer_ticker":"ACHN","issuer_name_source":null,"issuer_url":"/issuer/0001070336","owner_cik":null,"owner_name":"QVT Associates GP LLC; QVT Fund V LP","owner_display_name":"QVT Associates GP LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock, $0.001 par value","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":36300.0,"shares_display":"36,300","price_per_share":6.48,"price_display":"6.48","price_state":"stated","total_value":235224.0,"total_display":"235,224.00","total_whole":"235,224","shares_owned_after":14401871.0,"shares_owned_after_display":"14,401,871","ownership_form":"I","is_10b5_1":null,"transaction_date":"2013-08-08","filed_date":"2013-08-12","scope":"insider"},{"id":4690800,"accession":"0001181431-13-039975","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001181431-13-039975","line_url":"/filing/0001181431-13-039975","is_derivative":false,"issuer_cik":"0001070336","issuer_name":"ACHILLION PHARMACEUTICALS INC","issuer_ticker":"ACHN","issuer_name_source":null,"issuer_url":"/issuer/0001070336","owner_cik":null,"owner_name":"QVT Fund V LP; QVT Associates GP LLC","owner_display_name":"QVT Fund V LP","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock, $0.001 par value","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":401017.0,"shares_display":"401,017","price_per_share":6.4614877673515085,"price_display":"6.46","price_state":"stated","total_value":2591166.44,"total_display":"2,591,166.44","total_whole":"2,591,166","shares_owned_after":14305909.0,"shares_owned_after_display":"14,305,909","ownership_form":"I","is_10b5_1":null,"transaction_date":"2013-07-11","filed_date":"2013-07-15","scope":"insider","n_lines":2},{"id":4450488,"accession":"0001181431-13-039597","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001181431-13-039597","line_url":"/filing/0001181431-13-039597","is_derivative":false,"issuer_cik":"0001070336","issuer_name":"ACHILLION PHARMACEUTICALS INC","issuer_ticker":"ACHN","issuer_name_source":null,"issuer_url":"/issuer/0001070336","owner_cik":null,"owner_name":"QVT Associates GP LLC; QVT Fund V LP","owner_display_name":"QVT Associates GP LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock, $0.001 par value","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":190944.0,"shares_display":"190,944","price_per_share":6.364288587229764,"price_display":"6.36","price_state":"stated","total_value":1215222.72,"total_display":"1,215,222.72","total_whole":"1,215,223","shares_owned_after":13873610.0,"shares_owned_after_display":"13,873,610","ownership_form":"I","is_10b5_1":null,"transaction_date":"2013-07-10","filed_date":"2013-07-11","scope":"insider","n_lines":2},{"id":4450479,"accession":"0001181431-13-039597","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001181431-13-039597","line_url":"/filing/0001181431-13-039597#line-1","is_derivative":false,"issuer_cik":"0001070336","issuer_name":"ACHILLION PHARMACEUTICALS INC","issuer_ticker":"ACHN","issuer_name_source":null,"issuer_url":"/issuer/0001070336","owner_cik":null,"owner_name":"QVT Associates GP LLC; QVT Fund V LP","owner_display_name":"QVT Associates GP LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock, $0.001 par value","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":200000.0,"shares_display":"200,000","price_per_share":6.3,"price_display":"6.30","price_state":"stated","total_value":1260000.0,"total_display":"1,260,000.00","total_whole":"1,260,000","shares_owned_after":13773610.0,"shares_owned_after_display":"13,773,610","ownership_form":"I","is_10b5_1":null,"transaction_date":"2013-07-09","filed_date":"2013-07-11","scope":"insider"},{"id":5067148,"accession":"0001181431-13-039290","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001181431-13-039290","line_url":"/filing/0001181431-13-039290#line-3","is_derivative":false,"issuer_cik":"0001070336","issuer_name":"ACHILLION PHARMACEUTICALS INC","issuer_ticker":"ACHN","issuer_name_source":null,"issuer_url":"/issuer/0001070336","owner_cik":null,"owner_name":"QVT Fund V LP; QVT Associates GP LLC","owner_display_name":"QVT Fund V LP","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock, $0.001 par value","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":445209.0,"shares_display":"445,209","price_per_share":6.3,"price_display":"6.30","price_state":"stated","total_value":2804816.7,"total_display":"2,804,816.70","total_whole":"2,804,817","shares_owned_after":13573610.0,"shares_owned_after_display":"13,573,610","ownership_form":"I","is_10b5_1":null,"transaction_date":"2013-07-08","filed_date":"2013-07-09","scope":"insider"},{"id":5067144,"accession":"0001181431-13-039290","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001181431-13-039290","line_url":"/filing/0001181431-13-039290","is_derivative":false,"issuer_cik":"0001070336","issuer_name":"ACHILLION PHARMACEUTICALS INC","issuer_ticker":"ACHN","issuer_name_source":null,"issuer_url":"/issuer/0001070336","owner_cik":null,"owner_name":"QVT Fund V LP; QVT Associates GP LLC","owner_display_name":"QVT Fund V LP","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock, $0.001 par value","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":197300.0,"shares_display":"197,300","price_per_share":6.241677648251394,"price_display":"6.24","price_state":"stated","total_value":1231483.0,"total_display":"1,231,483.00","total_whole":"1,231,483","shares_owned_after":13056101.0,"shares_owned_after_display":"13,056,101","ownership_form":"I","is_10b5_1":null,"transaction_date":"2013-07-05","filed_date":"2013-07-09","scope":"insider","n_lines":2},{"id":5390951,"accession":"0001181431-13-039060","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001181431-13-039060","line_url":"/filing/0001181431-13-039060","is_derivative":false,"issuer_cik":"0001070336","issuer_name":"ACHILLION PHARMACEUTICALS INC","issuer_ticker":"ACHN","issuer_name_source":null,"issuer_url":"/issuer/0001070336","owner_cik":null,"owner_name":"QVT Associates GP LLC; QVT Fund V LP","owner_display_name":"QVT Associates GP LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock, $0.001 par value","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":463248.0,"shares_display":"463,248","price_per_share":6.243542119987566,"price_display":"6.24","price_state":"stated","total_value":2892308.4,"total_display":"2,892,308.40","total_whole":"2,892,308","shares_owned_after":12931101.0,"shares_owned_after_display":"12,931,101","ownership_form":"I","is_10b5_1":null,"transaction_date":"2013-07-03","filed_date":"2013-07-05","scope":"insider","n_lines":2},{"id":5390947,"accession":"0001181431-13-039060","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001181431-13-039060","line_url":"/filing/0001181431-13-039060","is_derivative":false,"issuer_cik":"0001070336","issuer_name":"ACHILLION PHARMACEUTICALS INC","issuer_ticker":"ACHN","issuer_name_source":null,"issuer_url":"/issuer/0001070336","owner_cik":null,"owner_name":"QVT Associates GP LLC; QVT Fund V LP","owner_display_name":"QVT Associates GP LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock, $0.001 par value","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1500000.0,"shares_display":"1,500,000","price_per_share":6.482333333333333,"price_display":"6.48","price_state":"stated","total_value":9723500.0,"total_display":"9,723,500.00","total_whole":"9,723,500","shares_owned_after":12467853.0,"shares_owned_after_display":"12,467,853","ownership_form":"I","is_10b5_1":null,"transaction_date":"2013-07-02","filed_date":"2013-07-05","scope":"insider","n_lines":3}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":0,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":0,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":0},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001679082","name":"Myovant Sciences Ltd.","url":"/issuer/0001679082","role":"Director, Ten percent owner, Other","n_filings":2,"first_seen":"2018-04-04","last_seen":"2019-06-06"},{"type":"issuer","type_label":"ISSUER","cik":"0001740547","name":"Urovant Sciences Ltd.","url":"/issuer/0001740547","role":"Ten percent owner","n_filings":1,"first_seen":"2018-10-03","last_seen":"2018-10-03"},{"type":"issuer","type_label":"ISSUER","cik":"0001636050","name":"Axovant Sciences Ltd.","url":"/issuer/0001636050","role":"Ten percent owner","n_filings":1,"first_seen":"2018-06-07","last_seen":"2018-06-07"},{"type":"issuer","type_label":"ISSUER","cik":"0001098972","name":"AGENUS INC","url":"/issuer/0001098972","role":"Ten percent owner","n_filings":1,"first_seen":"2015-01-13","last_seen":"2015-01-13"},{"type":"issuer","type_label":"ISSUER","cik":"0001367920","name":"CONCERT PHARMACEUTICALS, INC.","url":"/issuer/0001367920","role":"Ten percent owner","n_filings":1,"first_seen":"2014-02-21","last_seen":"2014-02-21"},{"type":"issuer","type_label":"ISSUER","cik":"0001070336","name":"ACHILLION PHARMACEUTICALS INC","url":"/issuer/0001070336","role":"Ten percent owner","n_filings":6,"first_seen":"2013-07-05","last_seen":"2013-10-02"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001543904","retrieved_at":"2026-08-26T04:32:29+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-24","last_ingest":"2026-08-25T05:24:19.374141+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}